Oak Hill Bio raised $32.5 million in a Series A financing.
- Amount
- $32.5M
- Stage
- Series A
- Announced
- 1 June 2026
- Leads
- Balyasny Asset Management, venBio, Janus Henderson Investors
- Other investors
- KCap Biotechnology Fund
- Use of funds
- Advance rugonersen into a pivotal Phase 3 clinical study for Angelman syndrome.
- Checked
- Amount and date checked against the press source